Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cefazolin · 1 trial · 1 indication
Cefazolin in plasma.
Cefazolin in plasma
Treatment Emergent Adverse Events (TEAEs)
| Arm | Type | Description |
|---|---|---|
| 3 g cefazolin | EXPERIMENTAL | Healthy adult subjects weighing ≥120 kg. (g=grams) |
| 2 g cefazolin | ACTIVE_COMPARATOR | Healthy adult subjects weighing \<120 kg. (g=grams) |
| Name | Type | Description |
|---|---|---|
| Cefazolin | DRUG | Cefazolin Injection - 2 g/100 mL or 3 g/150 mL |
Inclusion Criteria: * Subject provides informed consent (approved by an Institutional Review Board \[IRB\]) before any study specific evaluation is performed. * Subject is between the ages of 18 and 55 years (both inclusive). * A female subject is eligible to participate if she is not pregnant, bre...
Cefazolin is a small molecule antibiotic being studied for use in healthy volunteers. It is currently in Phase 1 clinical development, with a completed trial evaluating its pharmacokinetics at different doses. The drug is being developed by Baxter International Inc. (BAX).
Cefazolin is being developed by Baxter International Inc., a company traded on the New York Stock Exchange under the ticker BAX. The drug is currently in Phase 1 clinical development for use in healthy volunteers.
Cefazolin is in Phase 1 clinical development. It has one completed Phase 1 trial, which enrolled 24 healthy volunteers in the United States. The drug is investigational and has not been approved for any indication.
Cefazolin has one completed clinical trial, identified as NCT05309304, titled "Cefazolin PK Study 3g vs 2g." This Phase 1 study enrolled 24 healthy volunteers aged 18 years and older in the United States and evaluated the drug's pharmacokinetics.
Cefazolin is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The only trial for Cefazolin, NCT05309304, has been completed, but the drug remains under investigation and has not received regulatory approval.